Redeye retains its positive stance towards Hanza despite a softer Q2 report than expected regarding sales and margins. However, Hanza sees a strong inflow of new customers and expects a volume rebound in late 2024. We keep our mid- and long-term forecasts largely changed and expect Hanza to reach its 8% EBITA margin target in 2025.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/